JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

Search

Gilead Sciences Inc.

Chiusa

SettoreSettore sanitario

120.52 0.95

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

118.11

Massimo

120.53

Metriche Chiave

By Trading Economics

Entrata

-468M

1.3B

Vendite

-902M

6.7B

P/E

Media del settore

23.757

34.393

Rendimento da dividendi

2.74

Margine di Profitto

19.724

Dipendenti

17,600

EBITDA

-504M

2.6B

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+4.04% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

2.74%

2.54%

Prossima data del Dividendo

29 set 2025

Prossima data del' Ex Dividendo

15 set 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

10B

142B

Apertura precedente

119.57

Chiusura precedente

120.52

Notizie sul Sentiment di mercato

By Acuity

49%

51%

160 / 374 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

Gilead Sciences Inc. Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

7 ago 2025, 20:59 UTC

Utili

Gilead Sciences Upgrades Guidance After 2Q Results Top Views

24 apr 2025, 20:17 UTC

Utili

Gilead Sciences Swings to 1Q Profit, But Slashes FY25 EPS Guidance

8 ago 2025, 20:28 UTC

Utili

These Stocks Moved the Most Today: Trade Desk, Expedia, SoundHound, Pinterest, Gilead, Peloton, and More -- Barrons.com

8 ago 2025, 17:27 UTC

Utili

These Stocks Are Moving Most Today: Trade Desk, Expedia, SoundHound, Pinterest, Gilead, Microchip, and More -- Barrons.com

8 ago 2025, 12:03 UTC

Utili

These Stocks Are Moving Most Today: Trade Desk, Expedia, SoundHound, Pinterest, Firefly -- Barrons.com

8 ago 2025, 11:13 UTC

Utili

These Stocks Are Moving Most Today: Trade Desk, Expedia, SoundHound, Pinterest, Firefly -- Barrons.com

7 ago 2025, 21:13 UTC

Utili

Gilead Earnings Beat Estimates, But All Eyes Are On New HIV Shot -- Barrons.com

7 ago 2025, 20:44 UTC

Utili

Gilead Sciences Ups Guidance After 2Q Results Top Views

7 ago 2025, 20:26 UTC

Utili

Gilead Sciences: Liver Disease Portfolio Sales Decreased 4% to $795M in 2Q >GILD

7 ago 2025, 20:26 UTC

Utili

Gilead Sciences: 2Q Descovy Sales Increased 35% to $653M >GILD

7 ago 2025, 20:25 UTC

Utili

Gilead Sciences: HIV Pdt Sales Increased 7% to $5.1 B in 2Q >GILD

7 ago 2025, 20:24 UTC

Utili

Gilead Sciences: 2Q Biktarvy Sales Increased 9% Yr-Over-Yr to $3.5 B >GILD

7 ago 2025, 20:22 UTC

Utili

Gilead Sciences 2Q Adj EPS $2.01 >GILD

7 ago 2025, 20:22 UTC

Utili

Gilead Sciences 2Q Net $1.96B >GILD

7 ago 2025, 20:22 UTC

Utili

Gilead Sciences Sees FY EPS $5.85-EPS $6.15 >GILD

7 ago 2025, 20:22 UTC

Utili

Gilead Sciences 2Q Rev $7.1B >GILD

7 ago 2025, 20:22 UTC

Utili

Gilead Sciences 2Q Total Liver Disease Sales $211M >GILD

7 ago 2025, 20:22 UTC

Utili

Gilead Sciences Sees FY Adj EPS $7.95-Adj EPS $8.25 >GILD

7 ago 2025, 20:22 UTC

Utili

Gilead Sciences 2Q EPS $1.56 >GILD

27 apr 2025, 11:00 UTC

Notizie principali

Wall Street's New Tariff Safe Haven: High-Tax Biotech Stocks -- Heard on the Street -- WSJ

24 apr 2025, 20:08 UTC

Utili

Gilead Sciences Earnings Were Solid. How the S&P 500's No. 1 Health Stock Did. -- Barrons.com

24 apr 2025, 20:02 UTC

Utili

Gilead Sciences Sees 2025 Adj EPS $7.70-Adj EPS $8.10 >GILD

24 apr 2025, 20:02 UTC

Utili

Gilead Sciences: As of March 31, 2025, $7.9 Billion of Cash and Cash Equivalents Compared to $10.0 Billion as of Dec. 31, 2024 >GILD

24 apr 2025, 20:02 UTC

Utili

Gilead Sciences 1Q Rev $6.67B >GILD

24 apr 2025, 20:02 UTC

Utili

Gilead Sciences: 1Q Product Gross Margin Was 76.7% Compared to 76.6% in Same Period in 2024 >GILD

24 apr 2025, 20:02 UTC

Utili

Gilead Sciences: During 1Q Generated $1.8 Billion in Operating Cash Flow >GILD

24 apr 2025, 20:02 UTC

Utili

Gilead Sciences 1Q Adj EPS $1.81 >GILD

24 apr 2025, 20:02 UTC

Utili

Gilead Sciences: 1Q Lower Veklury (Remdesivir) and Oncology Sales Offset by Higher HIV and Liver Disease Sales >GILD

24 apr 2025, 20:02 UTC

Utili

Gilead Sciences Sees 2025 EPS $5.65-EPS $6.05 >GILD

24 apr 2025, 20:02 UTC

Utili

Gilead Sciences 1Q EPS $1.04 >GILD

Confronto tra pari

Modifica del prezzo

Gilead Sciences Inc. Previsione

Obiettivo di Prezzo

By TipRanks

4.04% in crescita

Previsioni per 12 mesi

Media 124.24 USD  4.04%

Alto 143 USD

Basso 98 USD

Basato su 22 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Gilead Sciences Inc. - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

22 ratings

18

Acquista

4

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

97.33 / 103.17Supporto e resistenza

A breve termine

Very Strong Bearish Evidence

A termine intermedio

Very Strong Bearish Evidence

A lungo termine

Weak Bullish Evidence

Sentiment

By Acuity

160 / 374 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Gilead Sciences Inc.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.